ENXTPA:AB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

AB Science S.A., a clinical-stage pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines.


Snowflake Analysis

Imperfect balance sheet with concerning outlook.

Share Price & News

How has AB Science's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.0%

AB

0.5%

FR Pharmaceuticals

1.6%

FR Market


1 Year Return

77.8%

AB

11.1%

FR Pharmaceuticals

-12.0%

FR Market

Return vs Industry: AB exceeded the French Pharmaceuticals industry which returned 11.1% over the past year.

Return vs Market: AB exceeded the French Market which returned -12% over the past year.


Shareholder returns

ABIndustryMarket
7 Day-1.0%0.5%1.6%
30 Day-7.4%-2.8%3.8%
90 Day4.4%-2.6%-17.0%
1 Year77.8%77.8%14.8%11.1%-10.2%-12.0%
3 Year-18.8%-18.8%8.7%-3.0%-0.6%-8.8%
5 Year-49.7%-49.7%18.4%-1.8%16.9%-0.4%

Price Volatility Vs. Market

How volatile is AB Science's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AB Science undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether AB Science is trading at an attractive price based on the cash flow it is expected to produce in the future. But as AB Science has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is AB Science forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

5.6%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if AB's forecast earnings growth is above the savings rate (0.6%).

Earnings vs Market: Insufficient data to determine if AB's earnings are forecast to grow faster than the French market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AB's revenue (5.6% per year) is forecast to grow faster than the French market (4% per year).

High Growth Revenue: AB's revenue (5.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has AB Science performed over the past 5 years?

-2.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AB is currently unprofitable.

Growing Profit Margin: AB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AB is unprofitable, and losses have increased over the past 5 years at a rate of -2.8% per year.

Accelerating Growth: Unable to compare AB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7%).


Return on Equity

High ROE: AB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is AB Science's financial position?


Financial Position Analysis

Short Term Liabilities: AB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: AB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: AB has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: AB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AB has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: AB is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is AB Science's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AB's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average board tenure


CEO

Alain Moussy

18.83yrs

Tenure

€482,000

Compensation

Mr. Alain Moussy, MBA is a Co-Founder of AB Science S.A. and has been its Chief Executive Officer since July 2001. Mr. Moussy has been Scientific Director at AB Science S.A. since January 2004. He serves a ...


CEO Compensation Analysis

Compensation vs Market: Alain's total compensation ($USD529.50K) is about average for companies of similar size in the French market ($USD668.91K).

Compensation vs Earnings: Alain's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Alain Moussy
Co-Founder18.83yrs€482.00k2.82% 10.4m
Jean-Pierre Kinet
Director18.83yrsno datano data
Patrick Moussy
Director18.83yrsno datano data
Brigitte Reverdin
Independent Director4.75yrsno datano data
Nathalie Riez
Director2.42yrsno datano data
Emmanuelle Mourey
Independent Director1.92yrsno datano data
Béatrice Bihr
1.92yrsno datano data

4.8yrs

Average Tenure

Experienced Board: AB's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.2%.


Top Shareholders

Company Information

AB Science S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AB Science S.A.
  • Ticker: AB
  • Exchange: ENXTPA
  • Founded: 2001
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €370.890m
  • Shares outstanding: 44.58m
  • Website: https://www.ab-science.com

Number of Employees


Location

  • AB Science S.A.
  • 3, Avenue George V
  • Paris
  • Ile-de-France
  • 75008
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ABENXTPA (Euronext Paris)YesCommon SharesFREURApr 2010
A8DDB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2010
0Q77LSE (London Stock Exchange)YesCommon SharesGBEURApr 2010
ABSC.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDApr 2010
ABPBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURApr 2010

Biography

AB Science S.A., a clinical-stage pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases. The company is also developing AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase II clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was founded in 2001 and is headquartered in Paris, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/27 22:31
End of Day Share Price2020/05/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.